IGC Pharma, Inc. (IGC) reported a quarterly loss of $0.02 per share, in line with expectations and an improvement from last year. The company has beaten EPS estimates three out of the last four quarters. Revenues for the quarter were $0.19 million, missing estimates by 56.59%. Stock performance has lagged behind the market.

Investors are now looking ahead to IGC Pharma, Inc.’s future performance. Earnings outlook and estimate revisions will play a crucial role in determining stock movement. The current Zacks Rank for IGC is #3 (Hold), suggesting performance in line with the market. Consensus estimates for upcoming quarters show a loss of -$0.02 per share on $0.31 million in revenues.

Another player in the industry, MediWound (MDWD), is set to report results soon. The company is expected to post a quarterly loss of $0.81 per share, representing a 17.4% increase from last year. Revenues are expected to reach $6.43 million, up 47.4% from the previous year.

For investors interested in IGC Pharma, Inc., research and analysis from Zacks Investment Research can provide valuable insights. With a history of outperforming the market, Zacks offers tools to track stock performance and earnings estimates. The company has consistently provided independent research and stock ratings since 1978.

Read more at Nasdaq: IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates